Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 3933 2023-06-27 07:27:30 |
2 layout + 6 word(s) 3939 2023-06-27 07:40:03 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Kciuk, M.; Yahya, E.B.; Mohamed, M.M.I.; Abdulsamad, M.A.; Allaq, A.A.; Gielecińska, A.; Kontek, R. Long Non-Coding RNAs in Gliomas. Encyclopedia. Available online: https://encyclopedia.pub/entry/46093 (accessed on 18 June 2024).
Kciuk M, Yahya EB, Mohamed MMI, Abdulsamad MA, Allaq AA, Gielecińska A, et al. Long Non-Coding RNAs in Gliomas. Encyclopedia. Available at: https://encyclopedia.pub/entry/46093. Accessed June 18, 2024.
Kciuk, Mateusz, Esam Bashir Yahya, Montaha Mohamed Ibrahim Mohamed, Muhanad A. Abdulsamad, Abdulmutalib A. Allaq, Adrianna Gielecińska, Renata Kontek. "Long Non-Coding RNAs in Gliomas" Encyclopedia, https://encyclopedia.pub/entry/46093 (accessed June 18, 2024).
Kciuk, M., Yahya, E.B., Mohamed, M.M.I., Abdulsamad, M.A., Allaq, A.A., Gielecińska, A., & Kontek, R. (2023, June 27). Long Non-Coding RNAs in Gliomas. In Encyclopedia. https://encyclopedia.pub/entry/46093
Kciuk, Mateusz, et al. "Long Non-Coding RNAs in Gliomas." Encyclopedia. Web. 27 June, 2023.
Long Non-Coding RNAs in Gliomas
Edit

Glioma progression refers to the development and growth of glioma tumors in the brain. Glioma progression is a complex and multifactorial process involving various genetic, molecular, and cellular changes. The prognosis and survival rates for gliomas differ between adults and pediatrics. Overall, pediatric gliomas tend to have better prognoses compared to gliomas in adults. This is partly due to the prevalence of low-grade tumors in children, which generally have better outcomes than high-grade tumors such as glioblastoma. However, certain pediatric gliomas, such as DIPG, have particularly poor prognoses. The mechanism of glioma progression involves a complex interplay of genetic, molecular, cellular, and microenvironmental factors. Generally, glioma progression is driven by the accumulation of genetic mutations.

glioma long RMA gene therapy brain tumors mutations

1. Long Non-Coding RNAs in Adult Gliomas

Adult gliomas primarily affect individuals over the age of 18, with the majority occurring in older adults. The most common adult glioma is glioblastoma multiforme, which is an aggressive and malignant tumor [1]. The CNS5 classification encompasses several types of adult gliomas with varying levels of malignancy. Each glioma type in the CNS5 classification has distinct histopathological features and grading criteria, which take into account factors such as nuclear atypia, mitotic activity, microvascular proliferation, and the presence of necrosis [2]. In addition to histological characteristics, the WHO classification also emphasizes the importance of molecular markers for certain glioma types, such as IDH mutation status, 1p/19q codeletion, and MGMT promoter methylation, which can have prognostic and predictive implications. Non-coding RNAs (ncRNAs) have been reported to play significant roles in glioma progression by regulating gene expression, cellular processes, and the tumor microenvironment [3]. LncRNAs can regulate gene expression through diverse mechanisms, including acting as scaffolds for protein complexes, interacting with DNA, RNA, or proteins, and modulating chromatin structure or transcriptional regulation [4]. Several lncRNAs have been implicated in glioma growth and invasion. Some lncRNAs promote glioma cell proliferation, survival, migration, and invasion by interacting with specific signaling pathways, such as the Wnt/β-catenin pathway or the PI3K/AKT pathway [5][6]. LncRNAs were also found to participate in epigenetic modifications, such as DNA methylation and histone modifications, influencing gene expression patterns in gliomas [7].
Different regulation mechanisms exerted by lncRNAs have been reported to influence adult glioma angiogenesis. LncRNAs can act as competing endogenous RNAs (ceRNAs) by sequestering miRNAs, thereby preventing their binding to target mRNAs. This interaction can modulate the expression of target genes and affect glioma progression [8]. Various lncRNAs have been identified as oncogenes or tumor suppressors in adult gliomas. For example, MALAT1, HOTAIR, and H19 have been found to promote glioma cell proliferation, migration, invasion, and angiogenesis, thereby acting as oncogenes [9][10][11]. Conversely, lncRNAs such as MEG3 and GAS5 have shown tumor-suppressive effects by inhibiting glioma cell growth and inducing apoptosis in adults [12]. Some lncRNAs can bind to proteins and modulate their activity, including transcription factors involved in angiogenesis-related gene expression. By recruiting transcription factors or interacting with other proteins, lncRNAs can regulate pathways that contribute to tumor angiogenesis. LncRNAs can also interact with other RNA molecules, such as mRNAs or miRNAs, to influence their stability, translation, or activity. This interaction can indirectly affect angiogenesis-related processes and pathways. Furthermore, lncRNAs can regulate the behavior and function of neighboring cells, including those within the tumor microenvironment. By influencing the communication between tumor cells and surrounding cells, lncRNAs can impact angiogenesis by promoting or inhibiting the formation of new blood vessels [13][14][15]. LncRNAs have essential roles in adult glioma cell proliferation and migration and guide gene regulation during tumor angiogenesis. They can directly regulate the cytoskeleton or influence the cytoskeleton through various signaling pathways during tumor migration [16]. Tang et al. [17] revealed that the long non-coding RNA-activated by transforming growth factor β (ATB) promoted the invasion of adults glioma cells through nuclear factor kappa B (NF-κB) and p38 mitogen-activated protein kinase (MAPK) pathways. Other lncRNAs were found to sponge miRNAs [18]. Dysregulated lncRNAs in gliomas have been associated with clinicopathological features, patient survival, and therapeutic response. They hold potential as diagnostic biomarkers and therapeutic targets for glioma treatment in adults. LncRNAs can modulate gene expression through epigenetic mechanisms in adult glioma. They can interact with chromatin-modifying proteins, such as polycomb repressive complexes (PRC1 and PRC2), to regulate the methylation and acetylation status of histones, thereby impacting gene transcription [19]. LncRNA HOTAIR is known to interact with PRC2 to silence tumor suppressor genes and promote adult glioma progression [20]. LncRNAs can regulate key signaling pathways involved in adult glioma pathogenesis, such as the PI3K/AKT, Wnt/β-catenin, and Notch pathways. They can modulate the expression or activity of pathway components, affecting downstream signaling events and promoting glioma cell survival, proliferation, and invasion. LncRNA CCAT2 has been found to activate the Wnt/β-catenin pathway in glioma cells, contributing to tumor growth [21]. While understanding of the precise functions and mechanisms of lncRNAs in adult glioma is still evolving, the emerging evidence suggests their important roles in glioma pathogenesis and their potential as therapeutic targets and biomarkers. Further research is needed to unravel the intricate interactions and regulatory networks involving lncRNAs in adult gliomas, paving the way for novel therapeutic strategies and improved patient outcomes.

2. Long Non-Coding RNAs in Pediatric Gliomas

Malignant brain and central nervous system (CNS) tumors account for ~21% of tumors in children and represent the second leading cause of pediatric cancer deaths after leukemia [22][23]. Pediatric glioma, a common central nervous system tumor in children, is classified into low-grade and high-grade categories. Low-grade gliomas refer to benign, slow-growing grade I or II lesions, while high-grade gliomas encompass rapidly progressing tumors such as anaplastic astrocytoma (grade III), glioblastoma, and diffuse intrinsic pontine glioma (grade IV) [24]. These non-coding RNA molecules have been found to be dysregulated in pediatric gliomas and contribute to tumor development and progression. Various lncRNAs have been identified as tumor suppressors or oncogenes in pediatric gliomas. For example, LINC00312 and MEG3 have been found to act as tumor suppressors, inhibiting glioma cell proliferation and inducing apoptosis [25]. On the other hand, lncRNAs such as MALAT1 and HOTAIR have been implicated as oncogenes, promoting glioma cell growth, invasion, and angiogenesis [26]. LncRNAs can modulate gene expression through epigenetic mechanisms in pediatric gliomas. They can interact with chromatin-modifying proteins and affect the methylation and acetylation status of histones, thereby regulating gene transcription. LncRNA H19, for instance, has been shown to play a role in the epigenetic silencing of tumor suppressor genes in pediatric gliomas [27]. LncRNAs can function as ceRNAs (competing endogenous RNAs) by sponging miRNAs and preventing them from binding to their target mRNAs. This interaction can impact the expression of target genes and affect glioma cell behavior. LncRNA HULC, for example, has been found to regulate miRNA-mediated gene expression in pediatric gliomas [28]. LncRNAs participate in the regulation of signaling pathways that are crucial for pediatric glioma pathogenesis. They can interact with key components of pathways, such as the PI3K/AKT and Wnt/β-catenin pathways, influencing downstream signaling events and cellular processes. LncRNA CCAT2 has been shown to activate the Wnt/β-catenin pathway in pediatric gliomas, promoting tumor growth [29]. Dysregulated expression of specific lncRNAs in pediatric gliomas has been associated with tumor grade, prognosis, and treatment response. These lncRNAs also hold promise as diagnostic and prognostic biomarkers for pediatric gliomas, aiding in patient stratification and personalized treatment decisions [30]. Understanding the roles of lncRNAs in pediatric gliomas provides insights into the molecular mechanisms underlying tumor development and may pave the way for the development of novel therapeutic strategies and targeted therapies.
The precise mechanisms through which lncRNAs exert their effects in both adults and pediatric glioma progression are still being explored. However, accumulating evidence suggests that lncRNAs play critical roles in regulating various cellular processes involved in tumor growth, invasion, metastasis, and treatment response. Figure 1 presents a summary of the role of long non-coding RNAs in human glioma progression.
Figure 1. The role of long non-coding RNAs in human glioma progression. The red arrows refer to down-regulation of the non-coding RNAs, while the green arrows refer to up-regulation.
In high-grade gliomas, the high expression of taurine-upregulated gene 1 (TUG1) lncRNA has been reported to favor angiogenesis by inhibiting the function of miR-299, which has a binding site for vascular endothelial growth factor (VEGF) [31]. Ye et al. [32] showed that the down-regulation of long intergenic non-protein coding RNA (LINC01116) suppresses the angiogenesis of adult glioma in vivo. The same authors suggested that LINC01116 may play a role in the post-transcriptional regulation of VEGF by binding to miR-31-5p. In the same manner, X-inactive specific transcript (XIST) sponges miR-485 in human glioma micro-vascular endothelial cells; hence, the binding of miR-485 enables SRY-box transcription factor 7 (SOX7) to increase the expression level of VEGF [33]. Additionally, Cheng et al. [34] identified a correlation between lncRNA XIST and miR-429 in adult glioma cells, which was found to highly affect angiogenesis. The authors also reported that XIST knockdown reduced glioma angiogenesis in vitro and in vivo. Likewise, small nucleolar RNA host gene 15 (SNHG15) lncRNA knockdown reduced the expression levels of pro-angiogenic factor cell division control protein 42 homolog (CDC42) and VEGF because the miR-153 was longer sponged and led to suppression of tumor angiogenesis in adult glioma cells [35]. RNA binding proteins were found to play critical roles in almost all gene expression steps, especially in transcription as well as post-transcriptional regulations [36]. Yang et al. [37] investigated the expression and the role of lncRNA LINC00346 in adults glioma angiogenesis regulation and demonstrated that ankyrin repeat and KH domain containing one protein (ANKHD1) and LINC00346 were highly up-regulated in adult glioma cells, whereas the zinc finger protein 655 (ZNF655) expression was decreased. The authors reported that the inhibition of ANKHD1, LINC00346, or the overexpression of ZNF655 impeded angiogenesis of the cells, suggesting that ANKHD1 targeted the long RNA LINC00346 and enhanced its stability, which then bound to ZNF655 mRNA via their Alu elements. Thereby, LINC00346 facilitated ZNF655 mRNA degradation via a staufen1 (STAU1) mediated mRNA decay mechanism. Furthermore, the promoter region of ANKHD1 was targeted by ZNF655 and formed the feedback loop of ANKHD1/LINC00346/ZNF655 that regulated the angiogenesis of adult glioma cells. Refer to Table 1 for the summary of different lncRNAs mechanisms in adult glioma progression and angiogenesis.

3. Long Non-Coding RNAs as Biomarkers in Adults and Pediatric Glioma Diagnosis

Long non-coding RNAs (lncRNAs) have shown promise as biomarkers for glioma diagnosis. Their dysregulated expression patterns in gliomas can serve as indicators of disease presence, classification, and prognosis [51]. Dysregulated expression of specific lncRNAs has been observed in gliomas compared to normal brain tissue. This aberrant expression can be detected using various techniques, such as quantitative polymerase chain reaction (qPCR), microarray analysis, or RNA sequencing [52]. The expression levels of certain lncRNAs have demonstrated diagnostic potential for differentiating gliomas from non-neoplastic brain tissue or other brain tumor types. Poor outcome of high-grade glioma patients has been linked to late-stage diagnosis and treatment due to low knowledge about the early stage of glioma, which cannot be observed with conventional diagnostic approaches [53]. However, even in aggressive therapy of human glioma with a combination of different treatment modalities many types of gliomas have been reported with having a pessimistic prognosis for survival [54][55]. The current gold standard for categorizing nervous system tumors, as outlined in the 2021 edition of the World Health Organization (WHO) classification, prioritizes molecular diagnosis over histologic diagnosis. In many countries, histological evaluation is still in use for different glioma diagnoses, which is difficult and sometimes not clear to acquire tissue because of its special anatomical position in the CNS. Furthermore, diagnosis of glioma using imaging methods such as magnetic resonance imaging and computed tomography before clinical diagnosis or treatment are widely used, but they have failed to improve the early diagnosis rate, which results in significant glioma spreading [56]. Recently, some tumor-related molecules, including different non-coding RNAs, have been reported to be significantly involved in the angiogenesis and progression of gliomas in pediatrics and have been investigated for being diagnostic or prognostic biomarkers [57]. LncRNAs have shown the ability to distinguish between different glioma subtypes, aiding in their accurate classification. For example, lncRNA expression profiles have been used to differentiate between glioblastoma and lower-grade gliomas (LGG), as well as to identify specific molecular subtypes within GBM [58]. The sensitivity, accuracy, and specificity of these molecular biomarkers are highly adequate for the evaluation of early diagnosis or prognosis of human glioma with reliable clinical significance. lncRNAs have multiple biological functions, including transcriptional control, chromatin remodeling, and post-transcriptional processing [59][60]. The expression levels of certain lncRNAs have been associated with the prognosis and overall survival of glioma patients. High expression of some lncRNAs has been correlated with poorer outcomes, including shorter survival times and increased tumor aggressiveness [61]. These lncRNAs can serve as prognostic biomarkers, providing valuable information for patient risk stratification and treatment decision-making. LncRNAs have the potential to predict the response of gliomas to specific treatments. For example, the expression levels of certain lncRNAs have been associated with resistance to chemotherapy or radiotherapy. Monitoring the expression of these lncRNAs could help identify patients who are more likely to benefit from certain treatment strategies or require alternative therapeutic approaches. Another advantage of lncRNAs as biomarkers is their potential for non-invasive detection. lncRNAs can be detected in various body fluids, including blood, cerebrospinal fluid (CSF), and urine [62]. This enables the development of minimally invasive or liquid biopsy-based approaches for glioma diagnosis and monitoring, reducing the need for invasive procedures, such as surgical biopsies.
Expression abnormalities of lncRNAs and miRNAs have been reported to be associated with the gliomas progression in both adults and pediatrics [63]. Recent studies have indicated that MALAT1 lncRNA has promising potential to serve as a diagnostic biomarker for gliomas and other cancers with sufficient specificity and sensitivity [3][64]. Up-regulation of the HOXA-AS3 lncRNA significantly promoted tumor progression, and it can be used to predict poor prognosis in glioma [65]. Wang et al. [66] investigated the role of the LINC00152 in high-grade glioma in adults and observed its expression was independently associated with poor prognosis of high-grade glioma. The authors also reported that the overall survival of the high-expression glioma group was significantly shorter than the low-expression group, while the knockdown of LINC00152 inhibited tumor growth in vivo, suggesting LINC00152 as a potential prognostic biomarker for high-grade glioma, especially in adults. Recent investigations have demonstrated the role of antisense lncRNAs in numerous biological processes, including tumor cell proliferation, invasion, survival, migration, and even apoptosis through multiple epigenetic modifications and chromatin remodeling [67][68]. It was reported that HAND2 antisense RNA 1 (HAND2-AS1) in endometrioid endometrial carcinoma was significantly down-regulated, and its overexpression considerably inhibited invasion and metastasis of tumor through inactivating neuromedin U [69]. In a different study, Han et al. [70] found that the HOXA11-AS lncRNA could serve as a diagnostic target and biomarker for glioma in adults as well as pediatrics. Similarly, Wu et al. [71] used RNA sequencing data to profile the differentially expressed antisense lncRNAs in various gliomas gathered from the Chinese Glioma Genome Atlas database and found convincing evidence of the possibility of using WDFY3 antisense RNA 2 (WDFY3-AS2) lncRNA as a novel valuable prognostic biomarker and diagnostic agent for diffuse glioma in adults. Wang et al. [72] analyzed expression profiles of four lncRNA, namely, AGAP2 antisense RNA 1 (AGAP2-AS1), long intergenic non-protein coding RNA 1198 (LINC01198), TPT1 antisense RNA 1 (TPT1-AS1) and MIR155 host gene (MIR155HG) of anaplastic astrocytomas patients. The authors found that TPT1-AS1 was postulated to have a significant protective role, while the other three (AGAP2-AS1, LINC01198, and MIR155HG) were suggested to be involved in tumor development as they were expressed more in the high-risk group.

4. Long Non-Coding RNAs in Adults and Pediatric Glioma Therapy

Long non-coding RNAs (lncRNAs) have emerged as potential therapeutic targets in glioma therapy. Their dysregulation in gliomas and involvement in various cellular processes make them attractive candidates for novel treatment strategies. LncRNAs affect cell behavior in several different ways, from epigenetic regulation, including recruitment of transcription factor, splicing regulation, and messenger RNA stability and translation [73]. Owing to the ability of lncRNAs to interact with DNA, RNA, and proteins, lncRNAs also involve chromatin modification, post-transcriptional modifications, and scaffolding [74]. Chen et al. [75] found that up-regulation of the expression of carbamoyl phosphate synthetase 1 intronic transcript 1 (CPS1-IT1) lncRNA resulted in a significant decrease in glioma proliferation, migration, and invasion abilities in adults, suggesting CPS1-IT1 as anti-oncogenic molecules in glioma treatment. In a different study, lncGRS-1 was found to be a glioma-specific therapeutic target in both adults and pediatrics. Using antisense oligonucleotides that targeted lncGRS-1, it was able to selectively decrease tumor growth and sensitize glioma cells to radiotherapy [76]. Ji et al. [77] found that the knockdown of the SWI/SNF complex antagonist associated with prostate cancer 1 (SChLAP1) lncRNA suppressed the growth of glioma in adults as it was found to be highly expressed. The authors reported that SChLAP1 was stabilized by its binding to heterogeneous nuclear ribonucleoprotein L (HNRNPL), which significantly enhanced the interaction with the protein alpha-actinin-4 (ACTN4). Urothelial carcinoma-associated 1 (UCA1) lncRNA was recently discovered as a proto-oncogene in the progression of many cancers, including glioma in adults and pediatrics [78]. UCA1 could promote glioma cell proliferation and cell cycle in adults through the up-regulation of cyclin D1 transcription. Targeting dysregulated lncRNAs through their silencing or inhibition is a potential therapeutic approach. This can be achieved using antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), short hairpin RNAs (shRNAs), or CRISPR/Cas9-mediated gene editing [79][80][81]. By reducing the expression or function of oncogenic lncRNAs, these strategies aim to inhibit glioma growth, invasion, and other malignant characteristics. Some lncRNAs act as key regulators of gene expression in gliomas. Targeting these lncRNAs can modulate the expression of downstream genes involved in glioma progression. By manipulating the expression or activity of specific lncRNAs, it is possible to influence critical pathways associated with tumor growth, angiogenesis, invasion, and therapy resistance. Huang et al. [82] up-regulated UCA1 in adult glioma cell lines and tissues using lentiviral vector transfections and observed a significant elevation in glioma cell invasion through the induction of epithelial-mesenchymal transition. The same authors reported that the growth of adult glioma cells was significantly suppressed upon the silencing of UCA1 in vivo, and the expression of circadian locomotor output cycles kaput (CLOCK) was also significantly lowered after UCA1 knockdown, suggesting the utility of targeting this lncRNA for adult glioma treatment.
Certain lncRNAs have been reported to participate in epigenetic regulation, influencing chromatin structure and gene expression patterns in gliomas [83]. Targeting these lncRNAs can alter the epigenetic landscape and restore normal gene expression profiles. This approach holds promise for reversing aberrant gene silencing and promoting tumor-suppressive pathways in glioma cells. Combining lncRNA-targeted therapies with other treatment modalities, such as chemotherapy or radiotherapy, is being explored. By targeting lncRNAs alongside traditional treatments, it may be possible to enhance treatment efficacy, overcome therapy resistance, and improve patient outcomes. LncRNA H19 has been reported in numerous publications as well as its role in promoting cancer cell growth and proliferation [84][85] by regulating the proteins that are involved in apoptosis, cell cycle regulation as well as glucose metabolism, and chemoresistance [86]. H19 is expressed in both hepatocellular carcinoma and adult glioma-associated endothelial cells within the exosomes, which promote tumor angiogenesis [87]. Zhao et al. [88] observed that the overexpression of H19 significantly promoted glioma cell proliferation and migration in adults. The autophagy of the tested cell lines was enhanced after the silencing of H19 and suppressed when the lncRNA was overexpressed. H19 overexpression inhibited the mechanistic target of rapamycin (mTOR) protein phosphorylation and promoted Unc-51-like kinase 1 (ULK1) phosphorylation. The regulation of mTOR signaling was found to be the mechanism by which H19 promotes the proliferation, migration, and autophagy of adult glioma cells [88]. In a different study, Sheng et al. [89] recently reported that p53 targeted lncRNA suppressor of tumorigenicity 7 antisense RNA 1 (ST7-AS1) acted as a significant tumor suppressor by interacting with polypyrimidine tract-binding protein 1 (PTBP1) to suppress the Wnt/β-catenin signaling pathway in adult and pediatric glioma. They contributed to significant inhibition of glioma cells migration, invasion, and proliferation, in addition to promoting the apoptosis of glioma cells. Down-regulation of PTBP1 occurred as a result of ST7-AS1 direct binding at the post-transcriptional level. Certain lncRNAs have been implicated in conferring resistance to therapies in gliomas [90]. Targeting these lncRNAs can sensitize glioma cells to standard treatments, making them more responsive to chemotherapy or radiation. This approach aims to enhance the effectiveness of existing therapies and improve treatment responses. In addition to targeting lncRNAs, certain lncRNAs themselves can be used as therapeutic agents. For example, engineered lncRNAs can be designed to exert specific functions, such as acting as decoys for miRNAs or as competitors for protein-protein interactions. These engineered lncRNAs can potentially modulate critical pathways and disrupt glioma progression. Table 2 provides a summary of studies that involved the manipulation of lncRNAs activity for glioma therapy.

References

  1. King, J.L.; Benhabbour, S.R. Glioblastoma Multiforme—A Look at the Past and a Glance at the Future. Pharmaceutics 2021, 13, 1053.
  2. Reuss, D.E. Updates on the WHO diagnosis of IDH-mutant glioma. J. Neuro-Oncol. 2023, 162, 461–469.
  3. Cheng, H.; Zhao, H.; Xiao, X.; Huang, Q.; Zeng, W.; Tian, B.; Ma, T.; Lu, D.; Jin, Y.; Li, Y. Long Non-coding RNA MALAT1 Upregulates ZEB2 Expression to Promote Malignant Progression of Glioma by Attenuating miR-124. Mol. Neurobiol. 2021, 58, 1006–1016.
  4. Fu, D.; Shi, Y.; Liu, J.-B.; Wu, T.-M.; Jia, C.-Y.; Yang, H.-Q.; Zhang, D.-D.; Yang, X.-L.; Wang, H.-M.; Ma, Y.-S. Targeting long non-coding RNA to therapeutically regulate gene expression in cancer. Mol. Ther. Nucleic Acids 2020, 21, 712–724.
  5. Pan, B.; Zhao, M.; Wang, N.; Xu, L.; Wu, T.; Li, Z. LncRNA RGMB-AS1 promotes glioma growth and invasion through miR-1200/HOXB2 axis. OncoTargets Ther. 2019, 12, 10107.
  6. Li, Q.; Dong, C.; Cui, J.; Wang, Y.; Hong, X. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme. J. Exp. Clin. Cancer Res. 2018, 37, 265.
  7. Mazurov, E.; Sizykh, A.; Medvedeva, Y.A. HiMoRNA: A Comprehensive Database of Human lncRNAs Involved in Genome-Wide Epigenetic Regulation. Non-Coding RNA 2022, 8, 18.
  8. Wang, L.; Cho, K.B.; Li, Y.; Tao, G.; Xie, Z.; Guo, B. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int. J. Mol. Sci. 2019, 20, 5758.
  9. Najafi, S.; Khatami, S.H.; Khorsand, M.; Jamali, Z.; Shabaninejad, Z.; Moazamfard, M.; Majidpoor, J.; Zarch, S.M.A.; Movahedpour, A. Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis. Exp. Cell Res. 2022, 418, 113294.
  10. Sur, S.; Ray, R.B. Emerging role of lncRNA ELDR in development and cancer. FEBS J. 2022, 289, 3011–3023.
  11. Chen, L.; Xie, Y.; Yu, M.; Gou, Q. Long noncoding RNAs in lung cancer: From disease markers to treatment roles. Cancer Manag. Res. 2022, 14, 1771–1782.
  12. Kumar, A.; Girisa, S.; Alqahtani, M.S.; Abbas, M.; Hegde, M.; Sethi, G.; Kunnumakkara, A.B. Targeting Autophagy Using Long Non-Coding RNAs (LncRNAs): New Landscapes in the Arena of Cancer Therapeutics. Cells 2023, 12, 810.
  13. Sheng, S.-R.; Wu, J.-S.; Tang, Y.-L.; Liang, X.-H. Long noncoding RNAs: Emerging regulators of tumor angiogenesis. Future Oncol. 2017, 13, 1551–1562.
  14. Teppan, J.; Barth, D.A.; Prinz, F.; Jonas, K.; Pichler, M.; Klec, C. Involvement of long non-coding RNAs (lncRNAs) in tumor angiogenesis. Non-Coding RNA 2020, 6, 42.
  15. Song, E. The Long and Short Non-Coding RNAs in Cancer Biology; Springer: Berlin/Heidelberg, Germany, 2016; Volume 927.
  16. Tang, Y.; He, Y.; Zhang, P.; Wang, J.; Fan, C.; Yang, L.; Xiong, F.; Zhang, S.; Gong, Z.; Nie, S. LncRNAs regulate the cytoskeleton and related Rho/ROCK signaling in cancer metastasis. Mol. Cancer 2018, 17, 77.
  17. Tang, F.; Wang, H.; Chen, E.; Bian, E.; Xu, Y.; Ji, X.; Yang, Z.; Hua, X.; Zhang, Y.; Zhao, B. LncRNA-ATB promotes TGF-β-induced glioma cells invasion through NF-κB and P38/MAPK pathway. J. Cell. Physiol. 2019, 234, 23302–23314.
  18. Mu, M.; Niu, W.; Zhang, X.; Hu, S.; Niu, C. LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway. Oncogene 2020, 39, 6879–6892.
  19. Franklin, K.A.; Shields, C.E.; Haynes, K.A. Beyond the marks: Reader-effectors as drivers of epigenetics and chromatin engineering. Trends Biochem. Sci. 2022, 47, 417–432.
  20. Xin, L.; Tan, Y.; Zhu, Y.; Cui, X.; Wang, Q.; Zhao, J.; Tian, S.; Xu, C.; Xiao, M.; Hong, B. EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT. Neuro-Oncology 2023, noad102.
  21. Zheng, Y.; Yang, Z.; Luo, K.; Li, X. Small-molecule natural products for reversing liver fibrosis based on modulation of HSCs activation: An update. Authorea Prepr. 2022.
  22. Melnyk, T.; Masiá, E.; Zagorodko, O.; Conejos-Sánchez, I.; Vicent, M.J. Rational design of poly-L-glutamic acid-palbociclib conjugates for pediatric glioma treatment. J. Control. Release 2023, 355, 385–394.
  23. Ward, E.; DeSantis, C.; Robbins, A.; Kohler, B.; Jemal, A. Childhood and adolescent cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 83–103.
  24. Gritsch, S.; Batchelor, T.T.; Gonzalez Castro, L.N. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer 2022, 128, 47–58.
  25. Pathania, A.S.; Smith, O.V.; Prathipati, P.; Gupta, S.C.; Challagundla, K.B. Clinical implications of noncoding RNAs in neuroblastoma patients. In Clinical Applications of Non-Coding RNAs in Cancer; Elsevier: Amsterdam, The Netherlands, 2022; pp. 409–431.
  26. Leung, D. Long non-coding RNA in glioblastoma invasion: Angiogenesis and mesenchymal transition via PI3K and Wnt signalling. Asia Pac. J. Mol. Biol. Biotechnol. 2023, 31, 36–52.
  27. Roh, J.; Im, M.; Kang, J.; Youn, B.; Kim, W. Long non-coding RNA in glioma: Novel genetic players in temozolomide resistance. Anim. Cells Syst. 2023, 27, 19–28.
  28. Teng, Y.; Mortazavi, D.; Sohrabi, B.; Mosallaei, M.; Nariman-Saleh-Fam, Z.; Bastami, M.; Mansoori, Y.; Daraei, A.; Vahed, S.Z.; Navid, S. Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer. J. Oncol. 2022, 2022, 4889807.
  29. Yin, X.; Lin, H.; Lin, L.; Miao, L.; He, J.; Zhuo, Z. LncRNAs and CircRNAs in cancer. MedComm 2022, 3, e141.
  30. Chen, Y.; Miao, L.; Lin, H.; Zhuo, Z.; He, J. The role of m6A modification in pediatric cancer. Biochim. Biophys. Acta (BBA)-Rev. Cancer 2022, 1877, 188691.
  31. Dai, X.; Liao, K.; Zhuang, Z.; Chen, B.; Zhou, Z.; Zhou, S.; Lin, G.; Zhang, F.; Lin, Y.; Miao, Y. AHIF promotes glioblastoma progression and radioresistance via exosomes. Int. J. Oncol. 2019, 54, 261–270.
  32. Ye, J.; Zhu, J.; Chen, H.; Qian, J.; Zhang, L.; Wan, Z.; Chen, F.; Sun, S.; Li, W.; Luo, C. A novel lncRNA-LINC01116 regulates tumorigenesis of glioma by targeting VEGFA. Int. J. Cancer 2020, 146, 248–261.
  33. Hu, C.; Bai, X.; Liu, C.; Hu, Z. Long noncoding RNA XIST participates hypoxia-induced angiogenesis in human brain microvascular endothelial cells through regulating miR-485/SOX7 axis. Am. J. Transl. Res. 2019, 11, 6487.
  34. Cheng, Z.; Li, Z.; Ma, K.; Li, X.; Tian, N.; Duan, J.; Xiao, X.; Wang, Y. Long non-coding RNA XIST promotes glioma tumorigenicity and angiogenesis by acting as a molecular sponge of miR-429. J. Cancer 2017, 8, 4106.
  35. Ma, Y.; Xue, Y.; Liu, X.; Qu, C.; Cai, H.; Wang, P.; Li, Z.; Li, Z.; Liu, Y. SNHG15 affects the growth of glioma microvascular endothelial cells by negatively regulating miR-153. Oncol. Rep. 2017, 38, 3265–3277.
  36. Banerjee, A.; Vest, K.E.; Pavlath, G.K.; Corbett, A.H. Nuclear poly (A) binding protein 1 (PABPN1) and Matrin3 interact in muscle cells and regulate RNA processing. Nucleic Acids Res. 2017, 45, 10706–10725.
  37. Yang, C.; Zheng, J.; Liu, X.; Xue, Y.; He, Q.; Dong, Y.; Wang, D.; Li, Z.; Liu, L.; Ma, J. Role of ANKHD1/LINC00346/ZNF655 feedback loop in regulating the glioma angiogenesis via staufen1-mediated mRNA decay. Mol. Ther. Nucleic Acids 2020, 20, 866–878.
  38. Zhao, W.-H.; Yuan, H.-Y.; Ren, X.-Y.; Huang, K.; Guo, Z.-Y. Association between expression of HOTAIR and invasiveness of gliomas, and its predictive value. Adv. Clin. Exp. Med. 2019, 28, 1179–1183.
  39. Zhang, K.; Sun, X.; Zhou, X.; Han, L.; Chen, L.; Shi, Z.; Zhang, A.; Ye, M.; Wang, Q.; Liu, C. Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner. Oncotarget 2015, 6, 537.
  40. Cai, G.; Zhu, Q.; Yuan, L.; Lan, Q. LncRNA SNHG6 acts as a prognostic factor to regulate cell proliferation in glioma through targeting p21. Biomed. Pharmacother. 2018, 102, 452–457.
  41. Liao, K.; Lin, Y.; Gao, W.; Xiao, Z.; Medina, R.; Dmitriev, P.; Cui, J.; Zhuang, Z.; Zhao, X.; Qiu, Y. Blocking lncRNA MALAT1/miR-199a/ZHX1 axis inhibits glioblastoma proliferation and progression. Mol. Ther. Nucleic Acids 2019, 18, 388–399.
  42. Li, Z.; Xu, C.; Ding, B.; Gao, M.; Wei, X.; Ji, N. Long non-coding RNA MALAT1 promotes proliferation and suppresses apoptosis of glioma cells through derepressing Rap1B by sponging miR-101. J. Neuro-Oncol. 2017, 134, 19–28.
  43. Liu, X.; Zhu, Q.; Guo, Y.; Xiao, Z.; Hu, L.; Xu, Q. LncRNA LINC00689 promotes the growth, metastasis and glycolysis of glioma cells by targeting miR-338-3p/PKM2 axis. Biomed. Pharmacother. 2019, 117, 109069.
  44. Jin, C.; Zhao, J.; Zhang, Z.-P.; Wu, M.; Li, J.; Xiao, G.-L.; Liu, B.; Liao, Y.-X.; Liu, J.-P. Long non-coding RNA GAS5, by up-regulating PRC2 and targeting the promoter methylation of miR-424, suppresses multiple malignant phenotypes of glioma. J. Neuro-Oncol. 2020, 148, 529–543.
  45. Liu, Q.; Yu, W.; Zhu, S.; Cheng, K.; Xu, H.; Lv, Y.; Long, X.; Ma, L.; Huang, J.; Sun, S. Long noncoding RNA GAS5 regulates the proliferation, migration, and invasion of glioma cells by negatively regulating miR-18a-5p. J. Cell. Physiol. 2019, 234, 757–768.
  46. Yu, G.; Li, S.; Liu, P.; Shi, Y.; Liu, Y.; Yang, Z.; Fan, Z.; Zhu, W. LncRNA TUG1 functions as a ceRNA for miR-6321 to promote endothelial progenitor cell migration and differentiation. Exp. Cell Res. 2020, 388, 111839.
  47. Zhao, H.; Peng, R.; Liu, Q.; Liu, D.; Du, P.; Yuan, J.; Peng, G.; Liao, Y. The lncRNA H19 interacts with miR-140 to modulate glioma growth by targeting iASPP. Arch. Biochem. Biophys. 2016, 610, 1–7.
  48. Jia, P.; Cai, H.; Liu, X.; Chen, J.; Ma, J.; Wang, P.; Liu, Y.; Zheng, J.; Xue, Y. Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a. Cancer Lett. 2016, 381, 359–369.
  49. Lang, H.-L.; Hu, G.-W.; Zhang, B.; Kuang, W.; Chen, Y.; Wu, L.; Xu, G.-H. Glioma cells enhance angiogenesis and inhibit endothelial cell apoptosis through the release of exosomes that contain long non-coding RNA CCAT2. Oncol. Rep. 2017, 38, 785–798.
  50. Lang, H.; Hu, G.; Chen, Y.; Liu, Y.; Tu, W.; Lu, Y.; Wu, L.; Xu, G. Glioma cells promote angiogenesis through the release of exosomes containing long non-coding RNA POU3F3. Eur. Rev. Med. Pharm. Sci. 2017, 21, 959–972.
  51. Gutschner, T.; Richtig, G.; Haemmerle, M.; Pichler, M. From biomarkers to therapeutic targets—The promises and perils of long non-coding RNAs in cancer. Cancer Metastasis Rev. 2018, 37, 83–105.
  52. Hosseini, E.S.; Meryet-Figuiere, M.; Sabzalipoor, H.; Kashani, H.H.; Nikzad, H.; Asemi, Z. Dysregulated expression of long noncoding RNAs in gynecologic cancers. Mol. Cancer 2017, 16, 107.
  53. Hishii, M.; Matsumoto, T.; Arai, H. Diagnosis and treatment of early-stage glioblastoma. Asian J. Neurosurg. 2019, 14, 589.
  54. Tykocki, T.; Eltayeb, M. Ten-year survival in glioblastoma. A systematic review. J. Clin. Neurosci. 2018, 54, 7–13.
  55. Ostrom, Q.T.; Cioffi, G.; Gittleman, H.; Patil, N.; Waite, K.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro-Oncology 2019, 21, v1–v100.
  56. Hutterer, M.; Hattingen, E.; Palm, C.; Proescholdt, M.A.; Hau, P. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro-Oncology 2015, 17, 784–800.
  57. Xiao, Y.; Zhang, L.; Song, Z.; Guo, C.; Zhu, J.; Li, Z.; Zhu, S. Potential diagnostic and prognostic value of plasma circulating microRNA-182 in human glioma. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2016, 22, 855.
  58. Lin, J.-z.; Lin, N.; Zhao, W.-j. Identification and validation of a six-lncRNA prognostic signature with its ceRNA networks and candidate drugs in lower-grade gliomas. Genomics 2020, 112, 2990–3002.
  59. Zhuo, H.; Tang, J.; Lin, Z.; Jiang, R.; Zhang, X.; Ji, J.; Wang, P.; Sun, B. The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma. Mol. Carcinog. 2016, 55, 209–219.
  60. Fang, Y.; Fullwood, M.J. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genom. Proteom. Bioinform. 2016, 14, 42–54.
  61. Bin, X.; Hongjian, Y.; Xiping, Z.; Bo, C.; Shifeng, Y.; Binbin, T. Research progresses in roles of LncRNA and its relationships with breast cancer. Cancer Cell Int. 2018, 18, 179.
  62. Lai, H.; Li, Y.; Zhang, H.; Hu, J.; Liao, J.; Su, Y.; Li, Q.; Chen, B.; Li, C.; Wang, Z. exoRBase 2.0: An atlas of mRNA, lncRNA and circRNA in extracellular vesicles from human biofluids. Nucleic Acids Res. 2022, 50, D118–D128.
  63. Zhu, Y.; Zhang, X.; Qi, L.; Cai, Y.; Yang, P.; Xuan, G.; Jiang, Y. HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas. Oncotarget 2016, 7, 14429.
  64. Wang, Z.; Katsaros, D.; Biglia, N.; Shen, Y.; Fu, Y.; Loo, L.W.; Jia, W.; Obata, Y.; Yu, H. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival. Breast Cancer Res. Treat. 2018, 171, 261–271.
  65. Wu, F.; Zhang, C.; Cai, J.; Yang, F.; Liang, T.; Yan, X.; Wang, H.; Wang, W.; Chen, J.; Jiang, T. Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma. Oncotarget 2017, 8, 53110.
  66. Wang, W.; Wu, F.; Zhao, Z.; Wang, K.Y.; Huang, R.Y.; Wang, H.Y.; Lan, Q.; Wang, J.F.; Zhao, J.Z. Long noncoding RNA LINC00152 is a potential prognostic biomarker in patients with high-grade glioma. CNS Neurosci. Ther. 2018, 24, 957–966.
  67. Peng, Z.; Liu, C.; Wu, M. New insights into long noncoding RNAs and their roles in glioma. Mol. Cancer 2018, 17, 61.
  68. Wang, S.; Wang, H.; Zhao, C.; Li, R. Long noncoding RNA LINC01426 promotes glioma progression through PI3K/AKT signaling pathway and serves as a prognostic biomarker. Eur. Rev. Med. Pharm. Sci. 2018, 22, 6358–6368.
  69. Yang, X.; Wang, C.C.; Lee, W.Y.W.; Trovik, J.; Chung, T.K.H.; Kwong, J. Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U. Cancer Lett. 2018, 413, 23–34.
  70. Wang, Q.; Zhang, J.; Liu, Y.; Zhang, W.; Zhou, J.; Duan, R.; Pu, P.; Kang, C.; Han, L. A novel cell cycle-associated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma. Cancer Lett. 2016, 373, 251–259.
  71. Wu, F.; Zhao, Z.; Chai, R.; Liu, Y.; Wang, K.; Wang, Z.; Li, G.; Huang, R.; Jiang, H.; Zhang, K. Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma. Cancer Cell Int. 2018, 18, 107.
  72. Wang, W.; Yang, F.; Zhang, L.; Chen, J.; Zhao, Z.; Wang, H.; Wu, F.; Liang, T.; Yan, X.; Li, J. LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas. Oncotarget 2016, 7, 77225.
  73. Abbastabar, M.; Kheyrollah, M.; Azizian, K.; Bagherlou, N.; Tehrani, S.S.; Maniati, M.; Karimian, A. Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification and transcriptional regulation for the control of cell growth: A double-edged sword protein. DNA Repair 2018, 69, 63–72.
  74. Dhanoa, J.K.; Sethi, R.S.; Verma, R.; Arora, J.S.; Mukhopadhyay, C.S. Long non-coding RNA: Its evolutionary relics and biological implications in mammals: A review. J. Anim. Sci. Technol. 2018, 60, 25.
  75. Chen, H.; Li, Q.; Liang, J.; Jin, M.; Lu, A. LncRNA CPS1-IT1 serves as anti-oncogenic role in glioma. Biomed. Pharmacother. 2019, 118, 109277.
  76. Liu, S.J.; Malatesta, M.; Lien, B.V.; Saha, P.; Thombare, S.S.; Hong, S.J.; Pedraza, L.; Koontz, M.; Seo, K.; Horlbeck, M.A. CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. Genome Biol. 2020, 21, 83.
  77. Ji, J.; Xu, R.; Ding, K.; Bao, G.; Zhang, X.; Huang, B.; Wang, X.; Martinez, A.; Wang, X.; Li, G. Long noncoding RNA SChLAP1 forms a growth-promoting complex with HNRNPL in human glioblastoma through stabilization of ACTN4 and activation of NF-κB signaling. Clin. Cancer Res. 2019, 25, 6868–6881.
  78. He, Z.; Wang, Y.; Huang, G.; Wang, Q.; Zhao, D.; Chen, L. The lncRNA UCA1 interacts with miR-182 to modulate glioma proliferation and migration by targeting iASPP. Arch. Biochem. Biophys. 2017, 623, 1–8.
  79. Pandya, G.; Kirtonia, A.; Sethi, G.; Pandey, A.K.; Garg, M. The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential. Biochim. Biophys. Acta (BBA)-Rev. Cancer 2020, 1874, 188423.
  80. Kciuk, M.; Yahya, E.B.; Mohamed Ibrahim Mohamed, M.; Rashid, S.; Iqbal, M.O.; Kontek, R.; Abdulsamad, M.A.; Allaq, A.A. Recent Advances in Molecular Mechanisms of Cancer Immunotherapy. Cancers 2023, 15, 2721.
  81. Ghani, A.R.I.; Yahya, E.B.; Allaq, A.A.; Khalil, A.S.A. Novel insights into genetic approaches in glioblastoma multiforme therapy. Biomed. Res. Ther. 2022, 9, 4851–4864.
  82. Huang, Z.; Zhao, X.; Wu, X.; Xiang, L.; Yuan, Y.; Zhou, S.; Yu, W. LncRNA UCA1 facilitated cell growth and invasion through the miR-206/CLOCK axis in glioma. Cancer Cell Int. 2019, 19, 316.
  83. Wang, C.; Wang, L.; Ding, Y.; Lu, X.; Zhang, G.; Yang, J.; Zheng, H.; Wang, H.; Jiang, Y.; Xu, L. LncRNA structural characteristics in epigenetic regulation. Int. J. Mol. Sci. 2017, 18, 2659.
  84. Luan, W.; Zhou, Z.; Ni, X.; Xia, Y.; Wang, J.; Yan, Y.; Xu, B. Long non-coding RNA H19 promotes glucose metabolism and cell growth in malignant melanoma via miR-106a-5p/E2F3 axis. J. Cancer Res. Clin. Oncol. 2018, 144, 531–542.
  85. Yan, J.; Zhang, Y.; She, Q.; Li, X.; Peng, L.; Wang, X.; Liu, S.; Shen, X.; Zhang, W.; Dong, Y. Long noncoding RNA H19/miR-675 axis promotes gastric cancer via FADD/Caspase 8/Caspase 3 signaling pathway. Cell. Physiol. Biochem. 2017, 42, 2364–2376.
  86. Si, X.; Zang, R.; Zhang, E.; Liu, Y.; Shi, X.; Zhang, E.; Shao, L.; Li, A.; Yang, N.; Han, X. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget 2016, 7, 81452.
  87. Conigliaro, A.; Costa, V.; Dico, A.L.; Saieva, L.; Buccheri, S.; Dieli, F.; Manno, M.; Raccosta, S.; Mancone, C.; Tripodi, M. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol. Cancer 2015, 14, 155.
  88. Zhao, W.; Lin, X.; Han, H.; Zhang, H.; Li, X.; Jiang, C.; Feng, M. Long noncoding RNA H19 contributes to the proliferation and autophagy of glioma cells through mTOR/ULK1 pathway. Neuroreport 2021, 32, 352–358.
  89. Sheng, J.; He, X.; Yu, W.; Chen, Y.; Long, Y.; Wang, K.; Zhu, S.; Liu, Q. p53-targeted lncRNA ST7-AS1 acts as a tumour suppressor by interacting with PTBP1 to suppress the Wnt/β-catenin signalling pathway in glioma. Cancer Lett. 2021, 503, 54–68.
  90. Ghafouri-Fard, S.; Agabalazadeh, A.; Abak, A.; Shoorei, H.; Hassanzadeh Taheri, M.M.; Taheri, M.; Sharifi, G. Role of long non-coding RNAs in conferring resistance in tumors of the nervous system. Front. Oncol. 2021, 11, 670917.
  91. Wen, H.; Li, Z.; Song, S.; Xu, L.; Tong, X.; Yan, H. Silencing of lncRNA LBX2-AS1 suppresses glioma cell proliferation and metastasis through the Akt/GSK3β pathway in vitro. Acta Biochim. Biophys. Sin. 2021, 53, 446–453.
  92. Qin, X.; Yao, J.; Geng, P.; Fu, X.; Xue, J.; Zhang, Z. LncRNA TSLC1-AS1 is a novel tumor suppressor in glioma. Int. J. Clin. Exp. Pathol. 2014, 7, 3065.
  93. Xu, L.-M.; Chen, L.; Li, F.; Zhang, R.; Li, Z.-y.; Chen, F.-F.; Jiang, X.-D. Over-expression of the long non-coding RNA HOTTIP inhibits glioma cell growth by BRE. J. Exp. Clin. Cancer Res. 2016, 35, 162.
  94. Li, H.; Yan, R.; Chen, W.; Ding, X.; Liu, J.; Chen, G.; Zhao, Q.; Tang, Y.; Lv, S.; Liu, S. Long non coding RNA SLC26A4-AS1 exerts antiangiogenic effects in human glioma by upregulating NPTX1 via NFKB1 transcriptional factor. FEBS J. 2021, 288, 212–228.
  95. Bi, C.-L.; Liu, J.-F.; Zhang, M.-Y.; Lan, S.; Yang, Z.-Y.; Fang, J.-S. LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p/MAP3K1 axis. Biosci. Rep. 2020, 40.
  96. Wang, A.; Meng, M.; Zhao, X.; Kong, L. Long non-coding RNA ENST00462717 suppresses the proliferation, survival, and migration by inhibiting MDM2/MAPK pathway in glioma. Biochem. Biophys. Res. Commun. 2017, 485, 513–521.
  97. Han, Y.; Wu, Z.; Wu, T.; Huang, Y.; Cheng, Z.; Li, X.; Sun, T.; Xie, X.; Zhou, Y.; Du, Z. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis. 2016, 7, e2123.
  98. Li, J.; Zhang, M.; An, G.; Ma, Q. LncRNA TUG1 acts as a tumor suppressor in human glioma by promoting cell apoptosis. Exp. Biol. Med. 2016, 241, 644–649.
  99. Luo, Q.; Zhang, F.; Li, W.; Wang, F.; Wu, L.; Huang, B. Overexpression of lncRNA MEG3 inhibits proliferation and invasion of glioblastoma U251 cells in vitro by suppressing HIF1α expression. Nan Fang Yi Ke Da Xue Xue Bao = J. South Med. Univ. 2021, 41, 141–145.
  100. Li, J.; Liao, T.; Liu, H.; Yuan, H.; Ouyang, T.; Wang, J.; Chai, S.; Li, J.; Chen, J.; Li, X. Hypoxic Glioma Stem Cell–Derived Exosomes Containing Linc01060 Promote Progression of Glioma by Regulating the MZF1/c-Myc/HIF1α Axis. Cancer Res. 2021, 81, 114–128.
More
Information
Subjects: Cell Biology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , , , , , ,
View Times: 270
Revisions: 2 times (View History)
Update Date: 27 Jun 2023
1000/1000
Video Production Service